Back to Search Start Over

Peripheral blood MR1 tetramer-positive mucosal-associated invariant T-cell function is modulated by mammalian target of rapamycin complex 1 in patients with active tuberculosis.

Authors :
Zhou CY
Yang YL
Han ZY
Chen YX
Liu HL
Fan K
Li MC
Tu SH
Wen Q
Zhou XY
Ma L
Source :
Immunology [Immunology] 2024 Nov; Vol. 173 (3), pp. 497-510. Date of Electronic Publication: 2024 Jul 18.
Publication Year :
2024

Abstract

Tuberculosis (TB) is still an urgent global public health problem. Notably, mucosal-associated invariant T (MAIT) cells play an important role in early anti-TB immune response. Targeted control of them may be an effective method to improve vaccine efficacy and TB treatment. However, the biology and signal regulation mechanisms of MAIT cells in TB patients are still poorly understood. Previous studies have been limited by the lack of reagents to specifically identify MAIT cells. In addition, the use of alternative markers may subsume non-MAIT cell into MAIT cell populations. In this study, the human MR1 tetramer which can specifically identify MAIT cells was used to further explore the effect and mechanism of MAIT cells in anti-TB immune response. Our results showed that the tetramer <superscript>+</superscript> MAIT cells in peripheral blood of TB patients were mainly CD8 <superscript>+</superscript> or CD4 <superscript>-</superscript> CD8 <superscript>-</superscript> cells, and very few were CD4 <superscript>+</superscript> cells. After BCG infecting autologous antigen-presenting cells, MAIT cells in patients produced significantly higher levels of cytokines, lysis and proliferation compared with healthy controls. After suppression of mTORC1 by the mTORC1-specific inhibitor rapamycin, the immune response of MAIT cells in patients was significantly reduced. This study demonstrates that peripheral blood tetramer <superscript>+</superscript> MAIT cells from TB patients have significant anti-TB immune effect, which is regulated by mTORC1. This could provide ideas and potential therapeutic targets for the development of novel anti-TB immunotherapy.<br /> (© 2024 The Author(s). Immunology published by John Wiley & Sons Ltd.)

Details

Language :
English
ISSN :
1365-2567
Volume :
173
Issue :
3
Database :
MEDLINE
Journal :
Immunology
Publication Type :
Academic Journal
Accession number :
39022997
Full Text :
https://doi.org/10.1111/imm.13834